Skip to main content










LeapUp - Open Innovation Program

Technological innovation has profoundly changed clinical practice and the relationship between health professionals and patients. Aware of this reality and of its role in the healthcare ecosystem, AbbVie is looking to collaborate with promising startups, to gain a clear vision of market trends and to be at the forefront of emerging technologies, open to unexpected novel opportunities that improve people’s lives.

The LeapUp Open Innovation Program aims to create an environment of collaborative innovation with startups that have the right fit with current challenges identified in specific therapeutic areas, giving them the opportunity to apply their projects with a leading client and a powerful brand to add value to the health ecosystem. 

Who Are We Looking For?

In this Open Innovation Program, we’re looking for startups that demonstrate the value of their solution to AbbVie Portugal and that can make a significant contribution to improve the lives of people with:

- Atopic Dermatitis

- Inflammatory

- Lymphoma

- Migraine

If you have an innovative solution that meet one of the program challenges and your startup is based in Europe or Israel 

Apply Here opens in a new window

The Challenges


Optimize healthcare professionals’ and patients’ experience in accessing information, converting a deeper knowledge of personal preferences, behaviors and information needs into the most meaningful and relevant communication to each individual, contributing to a better impact on patient's lives.


Accelerate the process of diagnosis, referral & implementation of novel treatment approaches and swiftly deliver the most recent information about guidelines, treatment targets and standards of care.


Improve disease awareness and patient health literacy to enable quicker access to the right specialist, increased knowledge of treatment options and understanding when current treatment stops achieving the desired goals.


Promote the collection & aggregation of real world clinical data, based on reported outcomes, to support better informed decisions by healthcare institutions, payors and the pharma industry towards a quicker access to novel therapies.


Do you want to provoke AbbVie Portugal to co-innovate with you by creating an unexpected matchmaking that will nurture a partnership to develop a new complementary business opportunity or even anticipate a future breakthrough challenge? 

At the end of the program, the selected startups can have the opportunity to further grow their business by exploring synergies, co-creating and co-developing new paths and future business opportunities directly with AbbVie Portugal in a Collaborative Partnership.

Regulation - Download opens in a new window

Check the Program Regulation  and if you are a startup from Europe or Israel interested in participating with your solution

Apply Here opens in a new window

If you have any questions regarding the program or the application process, please contact NOVA SBE Co.Innovation Lab:

E-mail:  [email protected]

WhatsApp: +351 915 446 975

Know more about The Promoters


AbbVie’s mission is to discover and deliver innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow. We work to make a remarkable impact on people’s lives in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, as well as through the products and services available in our Allergan Aesthetics portfolio. For more information about AbbVie, visit our website and follow @abbvie in Twitter, Facebook, LinkedIn or Instagram.


The Nova SBE Innovation Ecosystem (IECO), is a community  of innovators working towards a better and more sustainable future. By joining students, academia, corporates and startups, we’re creating a melting pot of changemakers ready to take on the future.​

As a key player of this ecosystem, the Co.Innovation Lab, leverages Nova SBE’s ecosystem, as a co-creation living lab to co-discover, co-create, and co-implement new solutions. Since our creation in 2017 we embrace open innovation programs, as part of our mission to create impact by transforming businesses and organizations in a collaborative and experimental way.